Industry
Biotechnology
ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.
Loading...
Open
4.58
Mkt cap
44M
Volume
3.5K
High
5.03
P/E Ratio
-9.84
52-wk high
5.82
Low
4.58
Div yield
N/A
52-wk low
3.34
Portfolio Pulse from
November 19, 2024 | 5:30 pm
Portfolio Pulse from
November 14, 2024 | 4:30 pm
Portfolio Pulse from
November 07, 2024 | 1:45 pm
Portfolio Pulse from Benzinga Newsdesk
October 08, 2024 | 8:08 pm
Portfolio Pulse from Benzinga Newsdesk
August 13, 2024 | 8:12 pm
Portfolio Pulse from Benzinga Newsdesk
June 05, 2024 | 8:21 pm
Portfolio Pulse from Benzinga Newsdesk
May 14, 2024 | 8:28 pm
Portfolio Pulse from Benzinga Newsdesk
May 08, 2024 | 5:02 pm
Portfolio Pulse from Benzinga Insights
April 09, 2024 | 8:31 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.